Iwatsuki S, Marsh J W, Starzl T E
Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh Transplantation Institute, Pennsyivania, USA.
Princess Takamatsu Symp. 1995;25:271-6.
During a 12-year period (1981-1992), 3,029 patients, including 220 with hepatocellular carcinoma (HCC), received their first orthotopic liver transplantation (OLTX) for various liver diseases. One-, three- and five-year survivals of these 220 patients with HCC were 68%, 46%, and 37%, respectively, and those of the 2,809 patients without HCC were 78%, 71%, and 67.0%, respectively. Among the 220 patients with HCC, the following factors were associated with a poor prognosis: multiple tumors, HCC in two lobes of the liver ("bilobar tumors"), micro- and macroscopic vascular invasion, lymph node metastasis, tumor within the surgical margin, Stage IV HCC, and male gender. Cirrhosis and detection of hepatitis B surface antigen (HBsAg) or antibody to hepatitis C virus (anti-HCV) did not influence the survival rates after OLTX in the presence of HCC. By multivariate analysis, the negative prognostic value of only vascular invasion, bilobar distribution, and lymph node metastasis reached significance. As vascular invasion of HCC was the most significant prognostic factor after OLTX, its incidence was examined according to the following three radiologic measurements of the HCC before operation: (1) size, (2) lobar distribution, and (3) number of HCC nodules. Fifty percent of the HCCs of greater than 5 cm diameter had macroscopic vascular invasion, and 1-, 3- and 5-year survivals of the patients with these HCCs were 60%, 30%, and 18%, respectively, after OLTX. Nearly 50% of the bilobar HCCs also had macroscopic vascular invasion, and 1-, 3- and 5-year survivals were 56%, 29%, and 15%, respectively, after OLTX. One-third of multiple tumors had macroscopic vascular invasion, and 1-, 3- and 5-year survivals were 64%, 38%, and 27%, respectively. However, survival after OLTX in patients with bilobar HCCs of < or = 2 cm diameter (even when these were Stage IV) was as good as in patients without HCC who had OLTX. The 5-year survival rate of the patients with unilobar, multiple HCCs without macroscopic vascular invasion, lymph node invasion and distant metastasis was 60%. These data indicate that HCCs of up to 5 cm diameter without macroscopic vascular invasion and nodal or distant metastasis can be effectively treated by OLTX.
在12年期间(1981 - 1992年),3029例患者因各种肝脏疾病接受了首次原位肝移植(OLTX),其中包括220例肝细胞癌(HCC)患者。这220例HCC患者的1年、3年和5年生存率分别为68%、46%和37%,而2809例非HCC患者的相应生存率分别为78%、71%和67.0%。在这220例HCC患者中,以下因素与预后不良相关:多发肿瘤、肝脏两叶出现HCC(“双叶肿瘤”)、微观和宏观血管侵犯、淋巴结转移、手术切缘内肿瘤、IV期HCC以及男性性别。肝硬化以及乙肝表面抗原(HBsAg)或丙肝病毒抗体(抗-HCV)的检测在存在HCC的情况下并不影响OLTX后的生存率。通过多因素分析,仅血管侵犯、双叶分布和淋巴结转移的负面预后价值具有统计学意义。由于HCC的血管侵犯是OLTX后最重要的预后因素,因此根据术前对HCC的以下三种影像学测量来检查其发生率:(1)大小,(2)叶分布,以及(3)HCC结节数量。直径大于5 cm的HCC中有50%存在宏观血管侵犯,这些HCC患者在OLTX后的1年、3年和5年生存率分别为60%、30%和18%。近50%的双叶HCC也存在宏观血管侵犯,OLTX后的1年、3年和5年生存率分别为56%、29%和15%。三分之一的多发肿瘤存在宏观血管侵犯,OLTX后的1年、3年和5年生存率分别为64%、38%和27%。然而,直径小于或等于2 cm的双叶HCC患者(即使处于IV期)OLTX后的生存率与非HCC接受OLTX患者的生存率相当。单叶、多发HCC且无宏观血管侵犯、淋巴结侵犯和远处转移患者的5年生存率为60%。这些数据表明,直径达5 cm且无宏观血管侵犯、无淋巴结或远处转移的HCC可通过OLTX得到有效治疗。